297 filings
6-K
PRQR
ProQR Therapeutics N.V
23 Apr 24
Current report (foreign)
7:06am
6-K
PRQR
ProQR Therapeutics N.V
19 Apr 24
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
7:06am
20-F
2023 FY
PRQR
ProQR Therapeutics N.V
Annual report (foreign)
13 Mar 24
8:43am
6-K
PRQR
ProQR Therapeutics N.V
13 Mar 24
ProQR Announces Year End 2023 Operating and Financial Results
7:10am
6-K
PRQR
ProQR Therapeutics N.V
15 Feb 24
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
7:46am
SC 13G/A
Van Herk Investments B.V.
14 Feb 24
ProQR Therapeutics / VAN HERK INVESTMENTS B.V. ownership change
6:08am
SC 13G/A
Van Herk Investments B.V.
9 Feb 24
ProQR Therapeutics / VAN HERK INVESTMENTS B.V. ownership change
6:37am
6-K
PRQR
ProQR Therapeutics N.V
19 Jan 24
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
7:08am
6-K
PRQR
ProQR Therapeutics N.V
5 Jan 24
Current report (foreign)
7:08am
6-K
PRQR
ProQR Therapeutics N.V
8 Dec 23
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
7:37am
6-K
PRQR
ProQR Therapeutics N.V
7 Nov 23
Current report (foreign)
10:00am
6-K
PRQR
ProQR Therapeutics N.V
27 Sep 23
ProQR Therapeutics Provides Update on Ophthalmic Assets
7:06am
SC 13G
Van Herk Investments B.V.
14 Sep 23
ProQR Therapeutics / VAN HERK INVESTMENTS B.V. ownership change
5:20pm
6-K
PRQR
ProQR Therapeutics N.V
3 Aug 23
Current report (foreign)
7:15am
6-K
PRQR
ProQR Therapeutics N.V
1 Aug 23
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
7:15am
6-K
PRQR
ProQR Therapeutics N.V
17 May 23
Current report (foreign)
4:05pm
6-K
PRQR
ProQR Therapeutics N.V
16 May 23
Current report (foreign)
7:15am
EFFECT
PRQR
ProQR Therapeutics N.V
25 Apr 23
Notice of effectiveness
12:15am
424B5
PRQR
ProQR Therapeutics N.V
24 Apr 23
Prospectus supplement for primary offering
4:30pm
CORRESP
PRQR
ProQR Therapeutics N.V
20 Apr 23
Correspondence with SEC
12:00am